{
    "clinical_study": {
        "@rank": "16755", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "89Zr-Trastuzumab Human Dosimetry and Safety"
            }, 
            {
                "arm_group_label": "Cohort 2: Lesion Detection and Safety", 
                "arm_group_type": "Experimental", 
                "description": "HER2 Positive Lesion Detection and Safety"
            }
        ], 
        "brief_summary": {
            "textblock": "The main purpose of this study is to see if Positron Emission Tomography (PET-Imaging) with\n      89Zr labeled trastuzumab can detect trastuzumab (HER2) positive breast cancer."
        }, 
        "brief_title": "89ZrTrastuzumab Breast Imaging With Positron Emission Tomography", 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female patients 18 years of age or older\n\n          -  Cohort 1: Her2-positive (defined as 3+) or FISH HER2:CEP17 ratio > 2 biopsy proven\n             breast cancer\n\n          -  Cohort 2: Her2-positive (defined as 3+) or FISH HER2:CEP17 ratio > 2 OR HER2negative\n             (0 or 1+, 2+ and FISH negative) biopsy-proven breast cancer\n\n          -  Primary or recurrent/metastatic lesion size \u2265 1.5 cm as determined by imaging studies\n             (ultrasonography,  mammography, CT or MRI) or physical examination\n\n          -  Able to give informed consent\n\n          -  Not currently pregnant or nursing:  Subject must be surgically sterile (has had a\n             documented bilateral oophorectomy and/or documented hysterectomy), postmenopausal\n             (cessation of menses for more than 1 year), non-lactating, or of  childbearing\n             potential for whom a urine pregnancy test (with the test performed within the 24 hour\n             period immediately prior to administration of 89Zr-trastuzumab) is negative\n\n          -  Patients currently receiving trastuzumab therapy with or without other types of\n             systemic therapy can participate if their disease progresses (development of new\n             lesion(s) or worsening of known lesion(s) based on imaging modalities or physical\n             examination.\n\n        Exclusion Criteria:\n\n          -  Patients with other invasive malignancies, with the exception of non- melanoma skin\n             cancer, who had (or have) any evidence of the other cancer present within the last 5\n             years\n\n          -  Unable to tolerate 60 min of PET imaging per imaging session"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "52", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02065609", 
            "org_study_id": "20130737", 
            "secondary_id": "R21CA182945"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort 1", 
                    "Cohort 2: Lesion Detection and Safety"
                ], 
                "description": "PET Imaging following administration of 89Zr labeled Trastuzumab for calculation of human dosimetry and overall safety", 
                "intervention_name": "89Zr-Trastuzumab Human Dosimetry and Safety", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Cohort 1", 
                    "Cohort 2: Lesion Detection and Safety"
                ], 
                "description": "Detection of HER2 Positive Breast Cancer with 89Zr Labeled Trastuzumab and PET imaging", 
                "intervention_name": "HER2 Positive Lesion Detection and Safety", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Trastuzumab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Trastuzumab", 
        "lastchanged_date": "February 14, 2014", 
        "location": {
            "contact": {
                "email": "fryej@mir.wustl.edu", 
                "last_name": "Jennifer Frye, CNMT, PET, CCRC", 
                "phone": "314-747-1604"
            }, 
            "contact_backup": {
                "email": "fryes@mir.wustl.edu", 
                "last_name": "Sarah Frye, MBA, CNMT, PET, NCT", 
                "phone": "314-362-7026"
            }, 
            "facility": {
                "address": {
                    "city": "Saint Louis", 
                    "country": "United States", 
                    "state": "Missouri", 
                    "zip": "63110"
                }, 
                "name": "Washington University School of Medicine @ Barnes-Jewish Hospital"
            }, 
            "investigator": {
                "last_name": "Farrokh Dehdashti, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Assessment of HER2 Receptors in Breast Carcinoma by Positron Emission Tomography (PET) Using 89 Zr-Trastuzumab", 
        "overall_contact": {
            "email": "fryej@mir.wustl.edu", 
            "last_name": "Jennifer Frye, CNMT, PET, CCRC", 
            "phone": "314-747-1604"
        }, 
        "overall_contact_backup": {
            "email": "fryes@mir.wustl.edu", 
            "last_name": "Sarah Frye, MBA, CNMT, PET, NCT", 
            "phone": "314-362-7026"
        }, 
        "overall_official": {
            "affiliation": "Washington University School of Medicine", 
            "last_name": "Farrokh Dehdashti, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "February 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability after  89Zr-Trastuzumab Administration", 
            "safety_issue": "Yes", 
            "time_frame": "30 Days following 89Zr-Trastuzumab Administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02065609"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Washington University School of Medicine", 
            "investigator_full_name": "Farrokh Dehdashti", 
            "investigator_title": "Profesior of Radiology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Washington University School of Medicine", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Washington University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}